These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Androgen receptor and hepatocarcinogenesis: what do we learn from HCC mouse models? Zender L; Kubicka S Gastroenterology; 2008 Sep; 135(3):738-40. PubMed ID: 18692055 [No Abstract] [Full Text] [Related]
26. Hepatocellular carcinoma: characteristics and current management. Sack J; Urist MM; Balch CM; Aldrete JS Ala J Med Sci; 1983 Apr; 20(2):182-5. PubMed ID: 6305227 [No Abstract] [Full Text] [Related]
27. Induction of angiopoietin-2 gene expression by COX-2: a novel role for COX-2 inhibitors during hepatocarcinogenesis. Tanaka S; Wands JR; Arii S J Hepatol; 2006 Jan; 44(1):233-5. PubMed ID: 16290311 [No Abstract] [Full Text] [Related]
28. Selective modification of sterol composition of hepatomas: new opportunities for chemotherapy. Feigin AM Med Hypotheses; 1999 May; 52(5):383-8. PubMed ID: 10416944 [TBL] [Abstract][Full Text] [Related]
30. Systemic therapy for hepatocellular carcinoma. Thomas MB Cancer J; 2008; 14(2):123-7. PubMed ID: 18391618 [TBL] [Abstract][Full Text] [Related]
31. Polyprenoic acid in hepatocellular carcinoma. Decensi A; Costa A N Engl J Med; 1996 Nov; 335(19):1461; author reply 1461-2. PubMed ID: 8927082 [No Abstract] [Full Text] [Related]
32. [Basic and clinical study of interferon a in hepatocellular carcinoma]. Sun HC; Wang L; Wu WZ Zhonghua Wai Ke Za Zhi; 2008 Nov; 46(21):1606-8. PubMed ID: 19094750 [No Abstract] [Full Text] [Related]
33. Thalidomide for advanced hepatocellular carcinoma: is this a real alternative? Wadler S Cancer; 2005 Jan; 103(1):1-4. PubMed ID: 15565637 [No Abstract] [Full Text] [Related]
34. [Targeted HCC therapies: the door has been opened!]. Rosmorduc O; Fartoux L Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):1-2. PubMed ID: 18341969 [No Abstract] [Full Text] [Related]
36. Tamoxifen does not improve overall survival in people with advanced-stage hepatocellular carcinoma. Chow PK Cancer Treat Rev; 2005 Oct; 31(6):491-5. PubMed ID: 16214294 [No Abstract] [Full Text] [Related]
37. "And what other medications are you taking?". Gordan JD; Chay WY; Kelley RK; Ko AH; Choo SP; Venook AP J Clin Oncol; 2011 Apr; 29(11):e288-91. PubMed ID: 21245436 [No Abstract] [Full Text] [Related]
39. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. Nakamura M; Nagano H; Sakon M; Yamamoto T; Ota H; Wada H; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Nakamori S; Dono K; Monden M J Hepatol; 2007 Jan; 46(1):77-88. PubMed ID: 17045692 [TBL] [Abstract][Full Text] [Related]
40. Systemic chemotherapy of hepatocellular carcinoma--Korean experience. Lee HC Oncology; 2008; 75 Suppl 1():114-8. PubMed ID: 19092280 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]